ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus(MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa. Source
No articles found.
Wright Medical Group N.V. is a global medical device company focused on Extremitie...
Wright Medical Group N.V. is a global medical d...
Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing ...
Seres Therapeutics, Inc. is a microbiome therap...
crooru is an on-demand, location-based app that connects health care staff and nur...
crooru is an on-demand, location-based app that...
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company develop...
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stag...
miRagen Therapeutics, Inc., is a clinical stage biopharmaceutical company discover...
miRagen Therapeutics, Inc., is a clinical stage...
Turning Point Therapeutics is a clinical-stage precision oncology company with a p...
Turning Point Therapeutics is a clinical-stage ...
Vir integrates diverse innovations in science, technology, and medicine to transfo...
Vir integrates diverse innovations in science, ...
Join the National Investor Network and get the latest information with your interests in mind.